Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 3/20 | 0.34 |
| ▸ | VCP | P55072 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948449 | 0.80 | ENPP2 (0.47) | ENPP2EPHX1CYP2D6EPHX2HSD11B1 | |
| SCHEMBL13137256 | 0.72 | NPC1 (0.52) | ENPP2KDM1AMAOAMAOBEPHX1 | |
| Acetic Acid SCHEMBL3038340 | 0.72 | HDAC1 (0.52) | ENPP2KDM1AMAOAMAOBEPHX1 | |
| Acetic Acid SCHEMBL3948445 | 0.72 | HDAC1 (0.52) | ENPP2KDM1AMAOAMAOBEPHX1 | |
| SCHEMBL13137259 | 0.65 | HDAC1 (0.48) | KDM1AMAOAMAOBNPC1HDAC1 | |
| SCHEMBL28972109 | 0.62 | SLC6A2 (0.44) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL3046293 | 0.61 | QPCT (0.35) | KDM1AHSD11B1PYGLHDAC1 | |
| SCHEMBL13137258 | 0.60 | EPHX1 (0.46) | ENPP2KDM1AMAOAMAOBEPHX1 | |
| SCHEMBL13137001 | 0.59 | QPCT (0.44) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL3034632 | 0.59 | ABCB1 (0.34) | KDM1AMAOAMAOBHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | ENPP2 593/4885KDM1A 4009/4885MAOA 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.